Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan/HCTZ in Uncontrolled Essential Hypertension
NCT00354991Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2006
- Primary completion
- Apr 2007
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of losartan and hydrochlorothiazide in essential hypertension, sponsored by Merck & Co. Primary endpoint: Percentage of patients reaching a blood pressure goal at 8 weeks. Started Jun 2006; status: completed.
02
Drugs
losartanhydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00354991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354991.